NovoCure Ltd Insider Trading for January 2021
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NovoCure Ltd.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in NovoCure Ltd for January 2021.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 14.37 | 36,396 | 523,011 | 0 | |
| Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 179.30 | 1,200 | 215,161 | 59,660 | 60.9 K to 59.7 K (-1.97 %) |
| Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 178.50 | 900 | 160,648 | 60,860 | 61.8 K to 60.9 K (-1.46 %) |
| Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 177.33 | 2,841 | 503,797 | 61,760 | 64.6 K to 61.8 K (-4.40 %) |
| Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 176.22 | 400 | 70,486 | 64,601 | 65 K to 64.6 K (-0.62 %) |
| Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 175.28 | 2,200 | 385,614 | 65,001 | 67.2 K to 65 K (-3.27 %) |
| Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 174.06 | 2,502 | 435,506 | 67,201 | 69.7 K to 67.2 K (-3.59 %) |
| Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 173.10 | 1,700 | 294,270 | 69,703 | 71.4 K to 69.7 K (-2.38 %) |
| Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 171.90 | 11,985 | 2,060,257 | 71,403 | 83.4 K to 71.4 K (-14.37 %) |
| Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 171.32 | 4,826 | 826,781 | 83,388 | 88.2 K to 83.4 K (-5.47 %) |
| Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 169.93 | 2,542 | 431,970 | 88,214 | 90.8 K to 88.2 K (-2.80 %) |
| Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 169.19 | 1,800 | 304,549 | 90,756 | 92.6 K to 90.8 K (-1.94 %) |
| Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 167.77 | 3,500 | 587,209 | 92,556 | 96.1 K to 92.6 K (-3.64 %) |
| Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 179.37 | 900 | 161,431 | 96,056 | 97 K to 96.1 K (-0.93 %) |
| Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 178.68 | 1,000 | 178,675 | 96,956 | 98 K to 97 K (-1.02 %) |
| Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 177.31 | 2,200 | 390,071 | 97,956 | 100.2 K to 98 K (-2.20 %) |
| Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 175.98 | 400 | 70,392 | 100,156 | 100.6 K to 100.2 K (-0.40 %) |
| Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 175.14 | 1,700 | 297,731 | 100,556 | 102.3 K to 100.6 K (-1.66 %) |
| Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 173.88 | 1,600 | 278,205 | 102,256 | 103.9 K to 102.3 K (-1.54 %) |
| Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 172.95 | 1,300 | 224,838 | 103,856 | 105.2 K to 103.9 K (-1.24 %) |
| Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 171.86 | 10,110 | 1,737,494 | 105,156 | 115.3 K to 105.2 K (-8.77 %) |
| Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 171.18 | 2,761 | 472,639 | 115,266 | 118 K to 115.3 K (-2.34 %) |
| Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 169.76 | 2,148 | 364,644 | 118,027 | 120.2 K to 118 K (-1.79 %) |
| Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 168.80 | 800 | 135,043 | 120,175 | 121 K to 120.2 K (-0.66 %) |
| Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 167.76 | 2,499 | 419,235 | 120,975 | 123.5 K to 121 K (-2.02 %) |
| Jan 19 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 14.37 | 36,396 | 523,011 | 123,474 | 87.1 K to 123.5 K (+41.80 %) |
| Jan 08 2021 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Grant | A | 50.67 | 93 | 4,712 | 142,700 | 142.6 K to 142.7 K (+0.07 %) |